Scott Bizily, the Chief Legal Officer at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), executed a substantial equity divestment on June 23, 2026. The transaction involved the sale of 9,810 shares of common stock, generating total proceeds of $117,720 at a price of $12.00 per share. This disposition occurred on the same day that Bizily exercised stock options to acquire the identical number of shares. The option exercise involved an acquisition price of $4.14 per share, totaling $40,613. The options, which carry an expiration date of March 5, 2035, followed a vesting schedule where 1/48th of the underlying shares became exercisable monthly beginning March 6, 2025.
Following the completion of these transactions, Bizily's direct holdings in 4D Molecular Therapeutics common stock stand at 8,617 shares. This reported ownership also accounts for an earlier acquisition of 5,023 shares facilitated through the company’s Employee Stock Purchase Plan. The sale occurs as FDMT trades near its 52-week high of $12.34, with the stock having delivered a 185% return over the past year. Market analysis indicates the stock may be undervalued at current levels, with additional financial metrics and ProTips available for investor review.
In corporate governance developments, 4D Molecular Therapeutics held its 2026 Annual Meeting of Stockholders virtually. During this meeting, stockholders elected three Class III directors to the board: Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA. These directors will serve until the 2029 Annual Meeting, based on SEC filing data showing strong support for each nominee. Concurrently, Jefferies adjusted its price target for 4D Molecular Therapeutics from $40.00 to $21.00 while maintaining a Buy rating. The firm cited the company's innovative gene therapy approach addressing durability in wet AMD as a key factor in its assessment. The company is currently conducting two pivotal trials, with results expected in the first and second halves of 2027.
The executive stock sale and concurrent corporate developments intersect with broader market dynamics. The biotechnology and gene therapy sectors are closely monitoring clinical trial timelines and analyst rating adjustments. The reduction in the price target by Jefferies, despite maintaining a Buy rating, reflects a recalibration of near-term valuation expectations for gene therapy developers. The strong stock performance of FDMT, including its 185% return, highlights investor interest in clinical catalysts and pipeline progression. However, the reliance on upcoming trial results in 2027 introduces timing risks that could impact market sentiment. The election of new directors also signals ongoing governance structures supporting the company's strategic initiatives. Investors are advised to review the comprehensive financial metrics and ProTips associated with FDMT to assess the risk-reward profile in the context of current market conditions.